Adicet Bio, Inc. - Common Stock (NQ:ACET)

7.700 -0.450 (-5.52%)

Streaming Delayed Price Updated: 12:16 PM EDT, Jun 5, 2026 Add to My Watchlist

Price and Volume

Volume	34,056
Open	8.050
Bid (Size)	7.640 (300)
Ask (Size)	7.700 (100)
Prev. Close	8.150
Today's Range	7.580 - 8.060
52wk Range	6.010 - 17.44
Shares Outstanding	42,957,586
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference ↗

June 04, 2026

Adicet Bio (NASDAQ:ACET) outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen...

Via MarketBeat

Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference

May 14, 2026

From Adicet Bio, Inc.

Via Business Wire

Performance

YTD	-12.7%	-12.7%
1 Month	-9.5%	-9.5%
3 Month	+3.2%	+3.2%
6 Month	-13.3%	-13.3%
1 Year	-39.2%	-39.2%

More News

Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

May 13, 2026

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

March 12, 2026

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

January 30, 2026

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

January 07, 2026

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Announces Reverse Stock Split

December 26, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

November 28, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 05, 2025

From Adicet Bio, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 04, 2025

Via Benzinga

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

October 31, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

October 28, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

October 16, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2 ↗

October 07, 2025

Via Benzinga

Tuesday's session: gap up and gap down stocks ↗

October 07, 2025

Via Chartmill

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

October 07, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

October 07, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

September 30, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 02, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 29, 2025

From Adicet Bio, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 19, 2025

Via Benzinga

Adicet Bio (ACET) Q2 Loss Widens 3% ↗

August 07, 2025

Via The Motley Fool

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 07, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

August 05, 2025

From Adicet Bio, Inc.

Via Business Wire

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

July 24, 2025

From Adicet Bio, Inc.

Via Business Wire

Frequently Asked Questions

Is Adicet Bio, Inc. - Common Stock publicly traded?

Yes, Adicet Bio, Inc. - Common Stock is publicly traded.

What exchange does Adicet Bio, Inc. - Common Stock trade on?

Adicet Bio, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Adicet Bio, Inc. - Common Stock?

The ticker symbol for Adicet Bio, Inc. - Common Stock is ACET on the Nasdaq Stock Market

What is the current price of Adicet Bio, Inc. - Common Stock?

The current price of Adicet Bio, Inc. - Common Stock is 7.700

When was Adicet Bio, Inc. - Common Stock last traded?

The last trade of Adicet Bio, Inc. - Common Stock was at 06/05/26 12:16 PM ET

What is the market capitalization of Adicet Bio, Inc. - Common Stock?

The market capitalization of Adicet Bio, Inc. - Common Stock is 330.77M

How many shares of Adicet Bio, Inc. - Common Stock are outstanding?

Adicet Bio, Inc. - Common Stock has 331M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.